Seeking Alpha

J&J (JNJ) won't enforce its patents on its HIV/AIDS drug Prezista in sub-Saharan Africa and...

J&J (JNJ) won't enforce its patents on its HIV/AIDS drug Prezista in sub-Saharan Africa and other poor countries, allowing generic pharmaceutical companies to manufacture cheap versions of the drug as long as the quality remains high. However, J&J won't share its IP in the new Medicines Patent Pool, saying it wants "to reserve the right to reinforce patents."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs